MR Imaging
OtherMR imaging
NCT Number: NCT01657734
Malignant gliomas are aggressive tumours with poor prognosis despite the current multimodal treatment. Hence, there is a clear need for new, effective therapies, among which immune therapy has emerged as a promising treatment option.
When interpreting follow-up magnetic resonance (MR) examinations, the radiologist is often confronted with images that are difficult to interpret with the conventional anatomical imaging techniques. The difference between tumour relapse and therapy-mediated changes is not always distinctive.
In this project, the investigators attempt to characterize the inflammatory response with parameters from advanced MRI techniques like MR spectroscopy, MR perfusion imaging and MR-diffusion imaging. These techniques allow characterization of cellular properties like metabolism and tissue structure respectively. Doing so, the investigators will monitor disease evolution in order to timely detect treatment failure, thereby allowing appropriate switch in patient management.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
University Hospitals Leuven, Leuven, Vlaams-Brabant, Belgium
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
**** patients enrolled in the HGG 2003 HGG-IMMUNO 2003 trial
Patients, older than 3 and younger than 60 years with relapse of high-grade glioma (anaplastic astrocytoma WHO grade III or glioblastoma multiforme WHO grade IV), histologically diagnosed in the first stage of the disease as well as after relapse or relapse of glioma which was grade II in the First phase but grade III or IV upon relapse are treated with dendritic cell therapy (immunotherapy) as single treatment approach (No radiotherapy and/or chemotherapy).
**** patients enrolled in the HGG 2010 HGG-IMMUNO 2010 trial
Exclusion criteria
minor age
MR imaging
Universitaire Ziekenhuizen KU Leuven
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02388659
Astrocytoma, Astrocytomas
Dallas, Texas, United States
View Trial DetailsNCT02155452
Glioma, Malignant Gliomas
Navi Mumbai, Maharashtra, India
View Trial DetailsNCT02731521
Astrocytoma, Astrocytomas
Dallas, Texas, United States
View Trial DetailsNCT00879437
Anaplastic Astrocytoma, Astrocytoma
Oklahoma City, Oklahoma, United States
View Trial Details